Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:81256
Name astrocytoma, IDH-mutant, grade 2
Definition An IDH-mutant anaplastic astrocytoma that is characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma anaplastic astrocytoma IDH-mutant anaplastic astrocytoma astrocytoma, IDH-mutant, grade 2

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
IDH1 act mut Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 act mut Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH1 R132X Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 R172X Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06478212 Phase Ib/II Temozolomide + Vorasidenib Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma Not yet recruiting USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT 2